Ruxolitinib prescription in myelofibrosis

被引：0
|
作者：
Lemal, Richard [1 ]
Robin, Marie [2 ]
Ravinet, Aurelie [1 ]
Cacheux, Victoria [1 ]
Guieze, Romain [1 ]
Bay, Jacques-Olivier [1 ]
机构：
[1] Univ Auvergne, Serv Hematol Clin Adulte & Therapie Cellulaire, CHU Clermont Ferrand, CHU Estaing,CREaT EA 7283,Inserm,CIC 501, F-63000 Clermont Ferrand, France
[2] Hop St Louis, AP HP, Serv Hematol Greffe, F-75010 Paris, France
来源：
BULLETIN DU CANCER | 2013年 / 100卷 / 09期
关键词：
ruxolitinib; primary myelofibrosis; myeloproliferative syndrome; splenomegaly; JAK2; INHIBITOR; INCB018424; PHARMACOKINETICS; TRANSPLANTATION; EFFICACY; SAFETY;
D O I：
10.1684/bdc.2013.1792
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, which allows to hope that we will soon be able to change the natural evolution of this poor outcome disease. With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America. In France, ruxolitinib is now available, allowing its administration to symptomatic myelofibrosis patients.
引用
收藏
页码：897 / 902
页数：6
相关论文
共 50 条
  • [1] Ruxolitinib for myelofibrosis
    Gu, Lian
    Su, Li
    Chen, Qing
    Xie, Juanjuan
    Wu, Guangliang
    Yan, Yan
    Liang, Baoyun
    Tan, Jinjing
    Tang, Nong
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (03) : 927 - 931
  • [2] Ruxolitinib (Jakafi) for Myelofibrosis
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1387): : 27 - 28
  • [3] Ruxolitinib In the Treatment of Myelofibrosis
    Yang, Lily P. H.
    Keating, Gillian M.
    [J]. DRUGS, 2012, 72 (16) : 2117 - 2127
  • [4] Ruxolitinib for Myelofibrosis REPLY
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Barosi, Giovanni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (21): : 2032 - 2034
  • [5] RUXOLITINIB FOR THE TREATMENT OF MYELOFIBROSIS
    Ostojic, A.
    Vrhovac, R.
    Verstovsek, S.
    [J]. DRUGS OF TODAY, 2011, 47 (11) : 817 - 827
  • [6] Efficacy of ruxolitinib for myelofibrosis
    Santos, Fabio P. S.
    Verstovsek, Srdan
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1465 - 1473
  • [7] Peritransplantation Use of Ruxolitinib in Myelofibrosis
    Ibrahim, Uroosa
    Petrone, Giulia Eva Maria
    Mascarenhas, John
    Keyzner, Alla
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (12) : 2177 - 2180
  • [8] Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
    Manduzio, Palma
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 169 - 177
  • [9] Ruxolitinib as an emerging treatment in myelofibrosis
    Emanuel, Robyn M.
    Geyer, Holly L.
    Mesa, Ruben A.
    [J]. BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2013, 3 : 11 - 18
  • [10] Ruxolitinib for the treatment of primary myelofibrosis
    Swaim, Starla J.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (06) : 453 - 462
12345